Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 23:9:27-35.
doi: 10.2147/RRU.S125791. eCollection 2017.

Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients

Henry H Woo  1 , Declan G Murphy  2 , Gerard M Testa  3 , Jeremy P Grummet  4 , Michael Chong  5 , Andrew P Stork  6
Affiliations

Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients

Henry H Woo et al. Res Rep Urol. .

Abstract

Purpose: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group.

Patients and methods: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia.

Results: Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events.

Conclusion: This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.

Keywords: GnRH agonist; IPSS.

PubMed Disclaimer

Conflict of interest statement

Disclosure DGM has received honoraria for speaking and consulting services from Ipsen Pty Ltd. JPG has received a research grant and honoraria for consulting services from Ipsen Pty Ltd. APS is an employee of Ipsen Pty Ltd. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Patient disposition. Abbreviation: IPSS, International Prostate Symptom Score.
Figure 2
Figure 2
Proportion of patients with moderate to severe LUTS (according to total IPSS) at all time points in the effectiveness population. Abbreviations: LUTS, lower urinary tract symptoms; IPSS, International Prostate Symptom Score.
Figure 3
Figure 3
Changes in quality of life during the study.
Figure 4
Figure 4
Median PSA at each time point in the effectiveness population. Abbreviation: PSA, prostate-specific antigen.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Labrie F, Belanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. 2005;26(3):361–379. - PubMed
    1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76–85. - PMC - PubMed
    1. Schroeder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981–990. - PMC - PubMed
    1. Lundstrom EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29(12):757–765. - PubMed
    1. Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE. Prevalence of lower urinary tract symptoms in men aged 45–79 years: a population-based study of 40 000 Swedish men. BJU Int. 2004;94(3):327–331. - PubMed

LinkOut - more resources